AR093758A1 - Inhibidores de aril lactama quinasa - Google Patents

Inhibidores de aril lactama quinasa

Info

Publication number
AR093758A1
AR093758A1 ARP130102716A ARP130102716A AR093758A1 AR 093758 A1 AR093758 A1 AR 093758A1 AR P130102716 A ARP130102716 A AR P130102716A AR P130102716 A ARP130102716 A AR P130102716A AR 093758 A1 AR093758 A1 AR 093758A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
haloalkyl
3amino
cycloalkyl
Prior art date
Application number
ARP130102716A
Other languages
English (en)
Spanish (es)
Inventor
M Vrudhula Vivekananda
Pan Senliang
Rajamani Ramkumar
Jethanand Nara Susheel
Sivasamban Karatholuvhu Maheswaran
Kumar Maishal Tarun
L Ditta Jonathan
Diane Dzierba Carolyn
J Bronson Joanne
E Macor John
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR093758A1 publication Critical patent/AR093758A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP130102716A 2012-07-31 2013-07-31 Inhibidores de aril lactama quinasa AR093758A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261677856P 2012-07-31 2012-07-31
US13/946,344 US8901305B2 (en) 2012-07-31 2013-07-19 Aryl lactam kinase inhibitors

Publications (1)

Publication Number Publication Date
AR093758A1 true AR093758A1 (es) 2015-06-24

Family

ID=50026068

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102716A AR093758A1 (es) 2012-07-31 2013-07-31 Inhibidores de aril lactama quinasa

Country Status (12)

Country Link
US (1) US8901305B2 (enExample)
EP (1) EP2880032B1 (enExample)
JP (1) JP2015528018A (enExample)
CN (1) CN104507941A (enExample)
AR (1) AR093758A1 (enExample)
BR (1) BR112015001890A2 (enExample)
CA (1) CA2880523A1 (enExample)
EA (1) EA201590268A1 (enExample)
ES (1) ES2602965T3 (enExample)
MX (1) MX2015000980A (enExample)
TW (1) TW201410676A (enExample)
WO (1) WO2014022167A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2958924B1 (en) 2013-02-22 2016-12-28 Bristol-Myers Squibb Company 5h-chromeno[3,4-c]pyridines as inhibitors of adaptor associated kinase 1 (aak1)
WO2015006100A1 (en) 2013-07-08 2015-01-15 Bristol-Myers Squibb Company Aryl amide kinase inhibitors
CN105979950A (zh) 2013-10-11 2016-09-28 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
EA028587B1 (ru) * 2014-01-29 2017-12-29 Бристол-Майерс Сквибб Компани Ариллактамные ингибиторы киназы
CA2944466C (en) * 2014-04-02 2020-06-09 Bristol-Myers Squibb Company Biaryl kinase inhibitors
EP3292124B1 (en) * 2015-04-10 2019-05-22 Bristol-Myers Squibb Company 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors
ES2767776T3 (es) * 2015-10-01 2020-06-18 Bristol Myers Squibb Co Inhibidores de biaril cinasa
CN112142655A (zh) * 2015-10-01 2020-12-29 百时美施贵宝公司 联芳基激酶抑制剂
US12636370B2 (en) * 2019-08-08 2026-05-26 Institute For Cancer Research Combination therapy for treatment of cancer
CN114853664B (zh) * 2022-06-02 2023-09-29 河南大学 一种钯催化条件下合成α,β-不饱和杂环己基酮类化合物的方法
CN116102542A (zh) * 2023-02-15 2023-05-12 如东众意化工有限公司 环丙唑醇精制母液中环丙唑醇的回收方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
DK0672031T3 (da) 1992-12-02 2003-06-10 Pfizer Catecholdiethere som selektive PDE IV-inhibitorer
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
ATE388946T1 (de) 2002-04-05 2008-03-15 Boehringer Ingelheim Pharma Cyanamide als reversible hemmer von cystein proteasen
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
EP1593667A4 (en) 2003-02-12 2009-03-04 Takeda Pharmaceutical Amine derivative
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
JP2007523109A (ja) * 2004-02-18 2007-08-16 エフ.ホフマン−ラ ロシュ アーゲー 複素環式Gaba−Aサブタイプ選択的レセプターモジュレーター
CA2570694A1 (en) 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
WO2007068465A1 (en) * 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
JP2007217408A (ja) 2006-01-19 2007-08-30 Tanabe Seiyaku Co Ltd 医薬組成物
AU2007223342A1 (en) * 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
JP5420395B2 (ja) 2006-04-07 2014-02-19 バーテックス ファーマシューティカルズ インコーポレイテッド Atp結合カセット輸送体の調節剤
US20080040819A1 (en) 2006-08-14 2008-02-14 Wyeth Methods of identifying agents for treatment of schizophrenia and related disorders
EP2094682A2 (en) * 2006-12-22 2009-09-02 Novartis AG Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
CA2761298A1 (en) * 2009-05-15 2010-11-18 The University Of Kentucky Research Foundation Treatment of mci and alzheimer's disease
FR2955109B1 (fr) * 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
EP2552922A1 (en) * 2010-03-31 2013-02-06 Bristol-Myers Squibb Company Substituted pyrrolotriazines as protein kinase inhibitors
HK1199814A1 (en) 2012-03-09 2015-07-24 Lexicon Pharmaceuticals, Inc. Inhibition of adaptor associated kinase 1 for the treatment of pain
RU2014140739A (ru) 2012-03-09 2016-04-27 Лексикон Фармасьютикалз, Инк. Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения
DK2834243T3 (en) 2012-03-09 2018-07-23 Lexicon Pharmaceuticals Inc Pyrazole [1,5-a] pyrimidine-based compounds, compositions comprising them and methods for their use
US8703953B2 (en) 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors

Also Published As

Publication number Publication date
JP2015528018A (ja) 2015-09-24
EP2880032B1 (en) 2016-10-05
EA201590268A1 (ru) 2015-05-29
ES2602965T3 (es) 2017-02-23
CA2880523A1 (en) 2014-02-06
MX2015000980A (es) 2015-04-10
BR112015001890A2 (pt) 2017-07-04
CN104507941A (zh) 2015-04-08
US8901305B2 (en) 2014-12-02
TW201410676A (zh) 2014-03-16
US20140038999A1 (en) 2014-02-06
EP2880032A1 (en) 2015-06-10
WO2014022167A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
AR100033A1 (es) Compuestos y composiciones para inhibir la actividad de shp2
AR100975A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR098872A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR091279A1 (es) Inhibidores macrociclicos de virus flaviviridae
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR097866A1 (es) Derivados de 4-azaindol
AR100807A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR110405A1 (es) Compuestos
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
ES2626555T3 (es) Pyridone amides como moduladores de canales de sodio
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
AR095359A1 (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR093515A1 (es) Triazolopirazinas
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR093579A1 (es) Inhibidores de bmi-1 de pirimidina inversa sustituida
AR088630A1 (es) Inhibidores del virus de la hepatitis c
AR100808A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR087909A1 (es) Composiciones farmaceuticas
AR099495A1 (es) Derivados de amida, antagonistas de orexina
AR091185A1 (es) Derivados de 1,2,4-triazol
AR095350A1 (es) Compuestos inhibidores de una histona deacetilasa y composición farmacéutica que los contiene
AR093057A1 (es) Inhibidores de la syk

Legal Events

Date Code Title Description
FB Suspension of granting procedure